Clinical trials: Professional Fulfillment

Breast Neoplasms

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

• Completed
• Age: 18 years and older
• Phase 2
• Injection or infusion
• Medical device
• Results posted

This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer.

Trial name

PrefHER (NCT01401166)

Testing

Herceptin, Single-Use Injection Device

Where

75 sites in Canada, Denmark and 10 more

Volunteers

488 people

Sponsor

Hoffmann-La Roche